These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36804126)

  • 1. XBB.1.5 Kraken cracked: Gibbs energies of binding and biosynthesis of the XBB.1.5 variant of SARS-CoV-2.
    Popovic ME
    Microbiol Res; 2023 May; 270():127337. PubMed ID: 36804126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Never ending story? Evolution of SARS-CoV-2 monitored through Gibbs energies of biosynthesis and antigen-receptor binding of Omicron BQ.1, BQ.1.1, XBB and XBB.1 variants.
    Popovic M
    Microb Risk Anal; 2023 Apr; 23():100250. PubMed ID: 36777740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread.
    Parums DV
    Med Sci Monit; 2023 Feb; 29():e939580. PubMed ID: 36722047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SARS-CoV-2 Hydra, a tiny monster from the 21st century: Thermodynamics of the BA.5.2 and BF.7 variants.
    Popovic M
    Microb Risk Anal; 2023 Apr; 23():100249. PubMed ID: 36777924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron Lineages - United States, January 2022-May 2023.
    Ma KC; Shirk P; Lambrou AS; Hassell N; Zheng XY; Payne AB; Ali AR; Batra D; Caravas J; Chau R; Cook PW; Howard D; Kovacs NA; Lacek KA; Lee JS; MacCannell DR; Malapati L; Mathew S; Mittal N; Nagilla RR; Parikh R; Paul P; Rambo-Martin BL; Shepard SS; Sheth M; Wentworth DE; Winn A; Hall AJ; Silk BJ; Thornburg N; Kondor R; Scobie HM; Paden CR
    MMWR Morb Mortal Wkly Rep; 2023 Jun; 72(24):651-656. PubMed ID: 37319011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Surveillance Reveals the Rapid Expansion of the XBB Lineage among Circulating SARS-CoV-2 Omicron Lineages in Southeastern Wisconsin, USA.
    Ramaiah A; Khubbar M; Akinyemi K; Bauer A; Carranza F; Weiner J; Bhattacharyya S; Payne D; Balakrishnan N
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant.
    Karyakarte RP; Das R; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Rajmane MV; Kulkarni PP; Nizarudeen S; Joshi S; Potdar V; Karmodiya K
    Cureus; 2023 Feb; 15(2):e35261. PubMed ID: 36968876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of peptide-functionalized or unfunctionalized selenium nanoparticles for the passivation of SARS-CoV-2 variants and the respiratory syncytial virus (RSV).
    Nahhas AF; Webster TJ
    Colloids Surf B Biointerfaces; 2024 Jan; 233():113638. PubMed ID: 37995630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant.
    Tamura T; Irie T; Deguchi S; Yajima H; Tsuda M; Nasser H; Mizuma K; Plianchaisuk A; Suzuki S; Uriu K; Begum MM; Shimizu R; Jonathan M; Suzuki R; Kondo T; Ito H; Kamiyama A; Yoshimatsu K; Shofa M; Hashimoto R; Anraku Y; Kimura KT; Kita S; Sasaki J; Sasaki-Tabata K; Maenaka K; Nao N; Wang L; Oda Y; ; Ikeda T; Saito A; Matsuno K; Ito J; Tanaka S; Sato K; Hashiguchi T; Takayama K; Fukuhara T
    Nat Commun; 2024 Feb; 15(1):1176. PubMed ID: 38332154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New variants of COVID-19 (XBB.1.5 and XBB.1.16, the "Arcturus"): A review of highly questioned concerns, a brief comparison between different peaks in the COVID-19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at-risk groups.
    Pourriyahi H; Hajizadeh N; Khosravi M; Pourriahi H; Soleimani S; Hosseini NS; Mohammad AP; Goodarzi A
    Immun Inflamm Dis; 2024 Jun; 12(6):e1323. PubMed ID: 38938013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2.
    Parums DV
    Med Sci Monit; 2023 Sep; 29():e942244. PubMed ID: 37654205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased vaccine sensitivity of an emerging SARS-CoV-2 variant.
    Lewnard JA; Hong V; Kim JS; Shaw SF; Lewin B; Takhar H; Lipsitch M; Tartof SY
    Nat Commun; 2023 Jun; 14(1):3854. PubMed ID: 37386005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo.
    Uraki R; Kiso M; Iwatsuki-Horimoto K; Yamayoshi S; Ito M; Chiba S; Sakai-Tagawa Y; Imai M; Kashima Y; Koga M; Fuwa N; Okumura N; Hojo M; Iwamoto N; Kato H; Nakajima H; Ohmagari N; Yotsuyanagi H; Suzuki Y; Kawaoka Y
    Cell Rep; 2023 Dec; 42(12):113580. PubMed ID: 38103202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative Genome-Based Survey of the SARS-CoV-2 Omicron XBB.1.16 Variant.
    Scarpa F; Azzena I; Ciccozzi A; Giovanetti M; Locci C; Casu M; Fiori PL; Borsetti A; Cella E; Quaranta M; Pascarella S; Sanna D; Ciccozzi M
    Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular In-Depth on the Epidemiological Expansion of SARS-CoV-2 XBB.1.5.
    Scarpa F; Azzena I; Locci C; Casu M; Fiori PL; Ciccozzi A; Angeletti S; Imperia E; Giovanetti M; Maruotti A; Borsetti A; Cauda R; Cassone A; Via A; Pascarella S; Sanna D; Ciccozzi M
    Microorganisms; 2023 Mar; 11(4):. PubMed ID: 37110335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An updated review of epidemiological characteristics, immune escape, and therapeutic advances of SARS-CoV-2 Omicron XBB.1.5 and other mutants.
    Liu Z; Li J; Pei S; Lu Y; Li C; Zhu J; Chen R; Wang D; Sun J; Chen K
    Front Cell Infect Microbiol; 2023; 13():1297078. PubMed ID: 38156316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of SARS-CoV-2 Omicron variant and strategies for tackling the infection.
    Wu Y; Long Y; Wang F; Liu W; Wang Y
    Immun Inflamm Dis; 2022 Dec; 10(12):e733. PubMed ID: 36444634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severity outcomes associated with SARS-CoV-2 XBB variants, an observational analysis.
    Klein EY; Fall A; Norton JM; Eldesouki RE; Abdullah O; Han L; Yunker M; Mostafa HH
    J Clin Virol; 2023 Aug; 165():105500. PubMed ID: 37290254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strain wars 2: Binding constants, enthalpies, entropies, Gibbs energies and rates of binding of SARS-CoV-2 variants.
    Popovic M
    Virology; 2022 May; 570():35-44. PubMed ID: 35366482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.